Top Markets
#1 Akedo Akedo +58.47%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.71%
#4 Cross Cross +45.85%
#5 Black Phoenix Black Phoenix +34.29%
#6 Velvet Velvet +30.75%
#7 Cap Cap +25.12%
#8 OVERTAKE OVERTAKE +20.17%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.83%
#10 Movement Movement +15.83%
Coin of the day
Akedo Akedo
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Aravive, Inc. Aravive, Inc.

Aravive, Inc.

ARAV
Classifica tra le azioni #38757
Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston,... Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway. This drug is currently progressing through a Phase III clinical trial for platinum-resistant recurrent ovarian cancer, and is also being evaluated in Phase Ib/II studies for clear cell renal cell carcinoma and pancreatic adenocarcinoma. Aravive also has AVB-S6 in its pipeline, a soluble Fc-fusion protein aimed at blocking the activation of the same GAS6-AXL pathway. Beyond internal development, Aravive has forged strategic partnerships. This includes a collaboration with WuXi Biologics (Hong Kong) Limited to develop novel, high-affinity bispecific antibodies targeting cancer and fibrosis. Furthermore, a license agreement with 3D Medicines Inc. grants rights to develop and commercialize products featuring batiraxcept as the sole active ingredient for human oncological diseases across mainland China, Taiwan, Hong Kong, and Macau. Originally incorporated in 2008 as Versartis, Inc., the company adopted the name Aravive, Inc. in October 2018.
Prezzo delle azioni
$0.0401
Ultima sincronizzazione: 2024-02-07
Capitalizzazione di mercato
$818.60K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Aravive, Inc. (ARAV)

Categoria

Healthcare
EPS per Aravive, Inc. (ARAV)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Aravive, Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per Aravive, Inc. da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE